Bloomberg
Media Bias by Omission: Bloomberg Doesn't Investigate Democratic Presidential Candidates
As of Nov. 2019, Bloomberg admits that it engages in bias by omission with a Lean Left bent. Mike Bloomberg, New York City mayor and founder of the financial software company that owns Bloomberg, officially entered the 2020 Democratic presidential race in Nov. 2019. According to a memo sent to editorial and research staff obtained by CNBC and verified by a Bloomberg spokesperson, Bloomberg News announced it would refrain from investigating Mayor Bloomberg and his Democratic rivals.
“We will continue our tradition of not investigating Mike (and his family and foundation ) and we will extend the same policy to his rivals in the Democratic primaries. We cannot treat Mike’s democratic competitors differently from him,” Editor-in-Chief John Micklethwait said in the memo.
In Dec. 2019, President Donald Trump's campaign announced it would stop credentialing Bloomberg News reporters for rallies and other events until the outlet resumed investigating Democratic candidates.
Mike Bloomberg is founder and 89% shareholder in Bloomberg LP, the financial software company that owns Bloomberg News.
Type of Content
Approved Story
1
Format
Hide on the following page types:
Front Page
Tag Pages
Topic Pages
Community Pages
Region
News Item Format
Standard
Story Cluster
Autocurated
1
External ID
5915882
Pfizer Inc. will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to compete with blockbuster weight-loss shots from Novo Nordisk A/S and Eli Lilly & Co.
The treatment, called danuglipron, was linked to a potentially drug-related liver injury in one patient enrolled in a clinical trial, Pfizer said in a statement. As a result, the company won’t advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity.